Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

[Effects of supplementation with the antioxidant flavonoid, silymarin, in chronic hepatitis C patients treated with peg-interferon + ribavirin. A placebo-controlled double blind study].

Pár A, Roth E, Miseta A, Hegedüs G, Pár G, Hunyady B, Vincze A.

Orv Hetil. 2009 Jan 11;150(2):73-9. doi: 10.1556/OH.2009.28517. Hungarian.

PMID:
19103558
2.

Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.

Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, Hofer H, Schöniger-Hekele M, Holzmann H, Steindl-Munda P.

Gastroenterology. 2008 Nov;135(5):1561-7. doi: 10.1053/j.gastro.2008.07.072. Epub 2008 Aug 3.

PMID:
18771667
3.

Effects of silymarin on hepatitis C virus and haem oxygenase-1 gene expression in human hepatoma cells.

Bonifaz V, Shan Y, Lambrecht RW, Donohue SE, Moschenross D, Bonkovsky HL.

Liver Int. 2009 Mar;29(3):366-73. doi: 10.1111/j.1478-3231.2008.01833.x. Epub 2008 Aug 7.

4.

Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2).

Miranda SR, Lee JK, Brouwer KL, Wen Z, Smith PC, Hawke RL.

Drug Metab Dispos. 2008 Nov;36(11):2219-26. doi: 10.1124/dmd.108.021790. Epub 2008 Aug 7.

5.

The effect of an iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells: a comparison with desferrioxamine.

Gharagozloo M, Khoshdel Z, Amirghofran Z.

Eur J Pharmacol. 2008 Jul 28;589(1-3):1-7. doi: 10.1016/j.ejphar.2008.03.059. Epub 2008 Apr 6.

PMID:
18619590
6.

The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity.

Schrieber SJ, Wen Z, Vourvahis M, Smith PC, Fried MW, Kashuba AD, Hawke RL.

Drug Metab Dispos. 2008 Sep;36(9):1909-16. doi: 10.1124/dmd.107.019604. Epub 2008 Jun 19.

7.

Effects of silymarin on the resolution of liver fibrosis induced by carbon tetrachloride in rats.

Tsai JH, Liu JY, Wu TT, Ho PC, Huang CY, Shyu JC, Hsieh YS, Tsai CC, Liu YC.

J Viral Hepat. 2008 Jul;15(7):508-14. doi: 10.1111/j.1365-2893.2008.00971.x. Epub 2008 Apr 4.

PMID:
18397225
8.

Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial.

Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, Shiffman ML, Lindsay KL, Lok AS, Di Bisceglie AM, Lee WM, Ghany MG; HALT-C Trial Group.

Hepatology. 2008 Feb;47(2):605-12.

9.

Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract.

Wen Z, Dumas TE, Schrieber SJ, Hawke RL, Fried MW, Smith PC.

Drug Metab Dispos. 2008 Jan;36(1):65-72. Epub 2007 Oct 3.

10.

Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin.

Polyak SJ, Morishima C, Shuhart MC, Wang CC, Liu Y, Lee DY.

Gastroenterology. 2007 May;132(5):1925-36. Epub 2007 Feb 21.

PMID:
17484885
11.

Peginterferon and ribavirin for chronic hepatitis C.

Hoofnagle JH, Seeff LB.

N Engl J Med. 2006 Dec 7;355(23):2444-51. Review. No abstract available.

PMID:
17151366
12.

A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients.

Flaig TW, Gustafson DL, Su LJ, Zirrolli JA, Crighton F, Harrison GS, Pierson AS, Agarwal R, Glodé LM.

Invest New Drugs. 2007 Apr;25(2):139-46. Epub 2006 Nov 1.

PMID:
17077998
13.

Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C.

Gordon A, Hobbs DA, Bowden DS, Bailey MJ, Mitchell J, Francis AJ, Roberts SK.

J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 2):275-80.

PMID:
16460486
14.

Silymarin treatment of viral hepatitis: a systematic review.

Mayer KE, Myers RP, Lee SS.

J Viral Hepat. 2005 Nov;12(6):559-67. Review.

PMID:
16255756
15.

Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results.

Tanamly MD, Tadros F, Labeeb S, Makld H, Shehata M, Mikhail N, Abdel-Hamid M, Shehata M, Abu-Baki L, Medhat A, Magder LS, Afdhal NH, Strickland GT.

Dig Liver Dis. 2004 Nov;36(11):752-9.

PMID:
15571006
16.

Stereoselective metabolism of silybin diastereoisomers in the glucuronidation process.

Han YH, Lou HX, Ren DM, Sun LR, Ma B, Ji M.

J Pharm Biomed Anal. 2004 Mar 10;34(5):1071-8.

PMID:
15019041
17.

Comparative bioavailability of silibinin in healthy male volunteers.

Kim YC, Kim EJ, Lee ED, Kim JH, Jang SW, Kim YG, Kwon JW, Kim WB, Lee MG.

Int J Clin Pharmacol Ther. 2003 Dec;41(12):593-6.

PMID:
14692709
18.

Silibinin protects mice from T cell-dependent liver injury.

Schümann J, Prockl J, Kiemer AK, Vollmar AM, Bang R, Tiegs G.

J Hepatol. 2003 Sep;39(3):333-40.

PMID:
12927918
19.

Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum).

Kim NC, Graf TN, Sparacino CM, Wani MC, Wall ME.

Org Biomol Chem. 2003 May 21;1(10):1684-9. Erratum in: Org Biomol Chem. 2003 Oct 7;1(19):3470.

PMID:
12926355
20.

Use of complementary and alternative medicine in patients with liver disease.

Strader DB, Bacon BR, Lindsay KL, La Brecque DR, Morgan T, Wright EC, Allen J, Khokar MF, Hoofnagle JH, Seeff LB.

Am J Gastroenterol. 2002 Sep;97(9):2391-7.

PMID:
12358262

Supplemental Content

Support Center